Financhill
Sell
9

PHAT Quote, Financials, Valuation and Earnings

Last price:
$5.53
Seasonality move :
-7.1%
Day range:
$4.40 - $4.89
52-week range:
$4.07 - $19.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.53x
P/B ratio:
--
Volume:
923.1K
Avg. volume:
1.1M
1-year change:
-42.99%
Market cap:
$337M
Revenue:
$55.3M
EPS (TTM):
-$5.35

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PHAT
Phathom Pharmaceuticals
$25.7M -$1.08 1351.14% -25.35% $21.63
AXSM
Axsome Therapeutics
$117.8M -$1.04 61.86% -6.01% $173.00
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 14.03% -95.43% $0.85
PTN
Palatin Technologies
-- -$0.42 -100% -67.93% $7.00
SYK
Stryker
$6.4B $3.87 8.28% 33.5% $424.43
TOVX
Theriva Biologics
-- -$5.50 -- -8.25% $6.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PHAT
Phathom Pharmaceuticals
$4.84 $21.63 $337M -- $0.00 0% 5.53x
AXSM
Axsome Therapeutics
$125.68 $173.00 $6.1B -- $0.00 0% 15.61x
NBY
NovaBay Pharmaceuticals
$0.64 $0.85 $3.1M -- $0.00 0% 0.07x
PTN
Palatin Technologies
$0.81 $7.00 $21.1M -- $0.00 0% --
SYK
Stryker
$373.49 $424.43 $142.5B 48.13x $0.84 0.87% 6.37x
TOVX
Theriva Biologics
$1.19 $6.00 $3.3M -- $0.00 0% 1.59x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PHAT
Phathom Pharmaceuticals
-386.06% -0.231 36.2% 3.92x
AXSM
Axsome Therapeutics
76.02% 1.366 4.39% 1.99x
NBY
NovaBay Pharmaceuticals
4.54% 0.646 1.51% 0.75x
PTN
Palatin Technologies
-- -1.737 -- 0.99x
SYK
Stryker
39.72% 1.452 10.13% 1.11x
TOVX
Theriva Biologics
-- -2.868 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PHAT
Phathom Pharmaceuticals
$25.8M -$59.4M -- -- -188.3% -$63.5M
AXSM
Axsome Therapeutics
$108.3M -$61.6M -96.73% -244.32% -61.14% -$26.2M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PTN
Palatin Technologies
-- -$5.1M -- -- -2356.3% -$4.8M
SYK
Stryker
$4.2B $1.6B 9.04% 15.22% 24.21% $1.7B
TOVX
Theriva Biologics
-- -$4.6M -- -- -- -$4.7M

Phathom Pharmaceuticals vs. Competitors

  • Which has Higher Returns PHAT or AXSM?

    Axsome Therapeutics has a net margin of -250.98% compared to Phathom Pharmaceuticals's net margin of -63.08%. Phathom Pharmaceuticals's return on equity of -- beat Axsome Therapeutics's return on equity of -244.32%.

    Company Gross Margin Earnings Per Share Invested Capital
    PHAT
    Phathom Pharmaceuticals
    87.14% -$1.05 -$52.2M
    AXSM
    Axsome Therapeutics
    91.15% -$1.54 $237.7M
  • What do Analysts Say About PHAT or AXSM?

    Phathom Pharmaceuticals has a consensus price target of $21.63, signalling upside risk potential of 346.8%. On the other hand Axsome Therapeutics has an analysts' consensus of $173.00 which suggests that it could grow by 37.65%. Given that Phathom Pharmaceuticals has higher upside potential than Axsome Therapeutics, analysts believe Phathom Pharmaceuticals is more attractive than Axsome Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PHAT
    Phathom Pharmaceuticals
    6 1 0
    AXSM
    Axsome Therapeutics
    12 0 0
  • Is PHAT or AXSM More Risky?

    Phathom Pharmaceuticals has a beta of 0.635, which suggesting that the stock is 36.461% less volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.342%.

  • Which is a Better Dividend Stock PHAT or AXSM?

    Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PHAT or AXSM?

    Phathom Pharmaceuticals quarterly revenues are $29.7M, which are smaller than Axsome Therapeutics quarterly revenues of $118.8M. Phathom Pharmaceuticals's net income of -$74.5M is higher than Axsome Therapeutics's net income of -$74.9M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 5.53x versus 15.61x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PHAT
    Phathom Pharmaceuticals
    5.53x -- $29.7M -$74.5M
    AXSM
    Axsome Therapeutics
    15.61x -- $118.8M -$74.9M
  • Which has Higher Returns PHAT or NBY?

    NovaBay Pharmaceuticals has a net margin of -250.98% compared to Phathom Pharmaceuticals's net margin of -49.65%. Phathom Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    PHAT
    Phathom Pharmaceuticals
    87.14% -$1.05 -$52.2M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About PHAT or NBY?

    Phathom Pharmaceuticals has a consensus price target of $21.63, signalling upside risk potential of 346.8%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.89%. Given that Phathom Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Phathom Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    PHAT
    Phathom Pharmaceuticals
    6 1 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is PHAT or NBY More Risky?

    Phathom Pharmaceuticals has a beta of 0.635, which suggesting that the stock is 36.461% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

  • Which is a Better Dividend Stock PHAT or NBY?

    Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PHAT or NBY?

    Phathom Pharmaceuticals quarterly revenues are $29.7M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Phathom Pharmaceuticals's net income of -$74.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 5.53x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PHAT
    Phathom Pharmaceuticals
    5.53x -- $29.7M -$74.5M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns PHAT or PTN?

    Palatin Technologies has a net margin of -250.98% compared to Phathom Pharmaceuticals's net margin of -2357.27%. Phathom Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PHAT
    Phathom Pharmaceuticals
    87.14% -$1.05 -$52.2M
    PTN
    Palatin Technologies
    -- -$0.12 -$111.5K
  • What do Analysts Say About PHAT or PTN?

    Phathom Pharmaceuticals has a consensus price target of $21.63, signalling upside risk potential of 346.8%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 764.09%. Given that Palatin Technologies has higher upside potential than Phathom Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Phathom Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    PHAT
    Phathom Pharmaceuticals
    6 1 0
    PTN
    Palatin Technologies
    0 0 0
  • Is PHAT or PTN More Risky?

    Phathom Pharmaceuticals has a beta of 0.635, which suggesting that the stock is 36.461% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

  • Which is a Better Dividend Stock PHAT or PTN?

    Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PHAT or PTN?

    Phathom Pharmaceuticals quarterly revenues are $29.7M, which are larger than Palatin Technologies quarterly revenues of $350K. Phathom Pharmaceuticals's net income of -$74.5M is lower than Palatin Technologies's net income of -$2.4M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 5.53x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PHAT
    Phathom Pharmaceuticals
    5.53x -- $29.7M -$74.5M
    PTN
    Palatin Technologies
    -- -- $350K -$2.4M
  • Which has Higher Returns PHAT or SYK?

    Stryker has a net margin of -250.98% compared to Phathom Pharmaceuticals's net margin of 8.48%. Phathom Pharmaceuticals's return on equity of -- beat Stryker's return on equity of 15.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    PHAT
    Phathom Pharmaceuticals
    87.14% -$1.05 -$52.2M
    SYK
    Stryker
    64.85% $1.41 $34.2B
  • What do Analysts Say About PHAT or SYK?

    Phathom Pharmaceuticals has a consensus price target of $21.63, signalling upside risk potential of 346.8%. On the other hand Stryker has an analysts' consensus of $424.43 which suggests that it could grow by 13.64%. Given that Phathom Pharmaceuticals has higher upside potential than Stryker, analysts believe Phathom Pharmaceuticals is more attractive than Stryker.

    Company Buy Ratings Hold Ratings Sell Ratings
    PHAT
    Phathom Pharmaceuticals
    6 1 0
    SYK
    Stryker
    13 9 0
  • Is PHAT or SYK More Risky?

    Phathom Pharmaceuticals has a beta of 0.635, which suggesting that the stock is 36.461% less volatile than S&P 500. In comparison Stryker has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.393%.

  • Which is a Better Dividend Stock PHAT or SYK?

    Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.87% to investors and pays a quarterly dividend of $0.84 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PHAT or SYK?

    Phathom Pharmaceuticals quarterly revenues are $29.7M, which are smaller than Stryker quarterly revenues of $6.4B. Phathom Pharmaceuticals's net income of -$74.5M is lower than Stryker's net income of $546M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while Stryker's PE ratio is 48.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 5.53x versus 6.37x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PHAT
    Phathom Pharmaceuticals
    5.53x -- $29.7M -$74.5M
    SYK
    Stryker
    6.37x 48.13x $6.4B $546M
  • Which has Higher Returns PHAT or TOVX?

    Theriva Biologics has a net margin of -250.98% compared to Phathom Pharmaceuticals's net margin of --. Phathom Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PHAT
    Phathom Pharmaceuticals
    87.14% -$1.05 -$52.2M
    TOVX
    Theriva Biologics
    -- -$1.60 --
  • What do Analysts Say About PHAT or TOVX?

    Phathom Pharmaceuticals has a consensus price target of $21.63, signalling upside risk potential of 346.8%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 404.2%. Given that Theriva Biologics has higher upside potential than Phathom Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Phathom Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    PHAT
    Phathom Pharmaceuticals
    6 1 0
    TOVX
    Theriva Biologics
    0 0 0
  • Is PHAT or TOVX More Risky?

    Phathom Pharmaceuticals has a beta of 0.635, which suggesting that the stock is 36.461% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

  • Which is a Better Dividend Stock PHAT or TOVX?

    Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PHAT or TOVX?

    Phathom Pharmaceuticals quarterly revenues are $29.7M, which are larger than Theriva Biologics quarterly revenues of --. Phathom Pharmaceuticals's net income of -$74.5M is lower than Theriva Biologics's net income of -$4.4M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 5.53x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PHAT
    Phathom Pharmaceuticals
    5.53x -- $29.7M -$74.5M
    TOVX
    Theriva Biologics
    1.59x -- -- -$4.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock